Stay updated on Nivolumab Post-HLA Mismatched BMT in Sarcoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Post-HLA Mismatched BMT in Sarcoma Clinical Trial page.
Latest updates to the Nivolumab Post-HLA Mismatched BMT in Sarcoma Clinical Trial page
- Check3 days agoChange DetectedRevision: v3.3.4 is now shown instead of v3.3.3; no changes to the study details or page behavior were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedAdded a consolidated Locations section listing Florida, Maryland, and New York sites. Removed the prior state-specific location subsections; page revision updated to v3.3.3.SummaryDifference0.4%
- Check54 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2 on the ClinicalTrials.gov page. No substantive changes to the study details are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check61 days agoChange DetectedA general government funding/operating status notice has been removed from the page. This does not affect the study details, eligibility criteria, or other trial information.SummaryDifference0.4%
- Check75 days agoChange DetectedThe page shows updated record metadata (latest update 2025-02-10) with no changes to core study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check104 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference3%
Stay in the know with updates to Nivolumab Post-HLA Mismatched BMT in Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Post-HLA Mismatched BMT in Sarcoma Clinical Trial page.